Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr

Pharmaceutical company Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr of 2011 compared to Rs 308 cr in a yr ago period.

Income are seen rising 8percent to Rs 2,091 cr compared to Rs 1,935 cr while the similar period.

EBITDA is likely to bounce 28percent to Rs 177 cr in July-September qtr of 2011 compared to Rs 139 cr in the similar qtr of last financial.

Operating_profit margin is anticipated to be at 8.5percent compared to 7percent yoy.

Be Sociable, Share!
Tags:

Stock Market Basics For Beginners

What Attention Should One Consider Before Investing?

What Attention Should One Consider Before Investing? [ad name="Banner 468 x 60 Text emage"] Golden rules for new investors Receive written docs describing the investment View and understand this kind of documents Confirm the authenticity of ...…

Preference Shares

Preference Shares Dividend that is first paid to preference shareholders before any dividends are paid to common stock holders, This shares represent partial ownership in a company ...…

National Stock Exchange Of India (NSE)

National Stock Exchange Of India (NSE) National Stock Exchange (NSE), found in the 1990s as a demutualised electronic exchange by Indian financial institutions.  Today, NSE is India's biggest exchange and second ...…

Bad Delivery

Bad Delivery Designation implying that a security doesn't fulfill all of the needs or have all the required endorsements to permit the certificate to be transferred to ...…

Definition for Bond

Definition for Bond A bond is a debt security issued for a period of more than one year with the purpose of raising capital by borrowing. The bonds ...…

Indian Share Tips

NSE Investment Site

Market Update

Share Guide

Designed by VMV
web
analytics